Wednesday, 22 October 2025
  
Login

Australia's most trusted
source of pharma news

Wednesday, 22 October 2025
News

Blockbuster keeps getting better

Posted 22 October 2025 AM

AstraZeneca hopes its antibody drug conjugate (ADC) Enhertu will become a foundational treatment for early stage breast cancer after delivering significant results in Phase 3 trials.

In the DESTINY-Breast11 trial, which assessed Enhertu in the neoadjuvant setting, about 67 per cent of patients with high-risk HER2-positive early-stage breast cancer achieved a pathological complete response (no evidence of invasive cancer in the breast tissue or lymph nodes) after being treated with Enhertu followed by a chemotherapy and HER2-targeting therapy regimen of Taxol, Herceptin and Perjeta (THP).

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (13)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (1)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.